Market Performance Analysis of Johnson & Johnson and Pfizer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 23 hours ago
0mins
Should l Buy JNJ?
Source: NASDAQ.COM
- Johnson & Johnson Revenue Growth: Johnson & Johnson recorded $88.8 billion in revenue for 2024, with projections of $94.2 billion for 2025 and an expected range of $99.5 billion to $100.5 billion for 2026, indicating a clearer business focus and enhanced growth following the spin-off of its consumer health division.
- Pfizer Revenue Decline: Pfizer's total revenue plummeted from approximately $100 billion in 2022 to $59.5 billion in 2023; while its drug development efforts, particularly in oncology and the acquisition of Seagen, suggest future growth potential, the short-term revenue stability remains a concern.
- Dividend Yield Comparison: Pfizer offers a dividend yield exceeding 6%, compared to Johnson & Johnson's 2.1%; although Pfizer's yield appears more attractive, Johnson & Johnson's consistent dividend increases over the past 60 years reflect its financial stability and sustainability.
- Market Outlook Assessment: In the current economic climate, Johnson & Johnson demonstrates higher growth potential due to its diverse product portfolio and steady cash flow, leading analysts to favor its future earnings capability, making it a suitable focus for long-term investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 241.310
Low
190.00
Averages
218.50
High
240.00
Current: 241.310
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strong Growth Amidst Significant Challenges for Johnson & Johnson
- Consistent Revenue Growth: Despite facing challenges such as patent expirations and drug pricing negotiations, Johnson & Johnson is projected to exceed $100 billion in revenue for 2023, demonstrating resilience and a strong market position in a tough environment.
- Significant Patent Risks: Johnson & Johnson lost patent protection for Stelara in 2023, which peaked at $10.9 billion in sales, accounting for nearly 13% of total revenue, posing a potential threat to future earnings.
- Robust Financial Foundation: The company holds an AAA rating from S&P Global, indicating a strong financial position capable of weathering potential lawsuits and market fluctuations, thereby enhancing investor confidence.
- Stable Dividend Policy: With 63 consecutive years of dividend increases, Johnson & Johnson is an ideal choice for investors seeking stable income amid economic uncertainty, further solidifying its leadership in the healthcare sector.
See More
Bristol Myers Squibb: A New Value Investment Choice
- Valuation Appeal: Bristol Myers Squibb's forward P/E ratio of approximately 9.5 makes it an attractive value stock compared to competitors like Johnson & Johnson and Merck, which have ratios of 21 and 24, potentially drawing interest from value-focused investors.
- Stable Dividend Yield: With a dividend yield of 4.2% and a history of 94 consecutive years of dividend payments, including 17 years of increases, the company demonstrates strong cash flow and commitment to shareholders, bolstering investor confidence.
- Revenue Growth Potential: While revenue for 2024 and 2025 is projected at $48.3 billion and $48.2 billion respectively, with a decline expected in 2026 to between $46 billion and $47.5 billion, the growth portfolio's revenue increased from $22.6 billion to $26.4 billion, indicating strong potential in new drug development.
- Acquisition Strategy: The planned $1.5 billion acquisition of Orbital Therapeutics, despite the existing $47 billion debt, could enhance Bristol's pipeline and help mitigate revenue losses from upcoming patent cliffs, showcasing a strategic vision for long-term growth.
See More
Investment Analysis of Bristol Myers Squibb
- Stable Revenue Performance: Bristol Myers Squibb reported revenues of $48.3 billion in 2024 and $48.2 billion in 2025, with a projected decline to between $46 billion and $47.5 billion in 2026, yet its revenue stability continues to attract investor interest.
- High Dividend Appeal: The company boasts a dividend yield of 4.2%, significantly higher than its competitors, and has increased its dividend for 17 consecutive years while paying dividends for 94 years, demonstrating strong cash flow and shareholder return capabilities.
- Growth Potential and Acquisition Plans: Bristol plans to acquire Orbital Therapeutics for $1.5 billion, which, despite its $47 billion debt, could enhance its drug pipeline and help mitigate revenue losses from upcoming patent cliffs.
- Market Concerns and Value Investment: While the market is worried about declining revenue from its legacy portfolio, Bristol's growth portfolio saw an increase from $22.6 billion to $26.4 billion in 2025, indicating potential in new drug development that may offer long-term value for investors.
See More
Bristol Myers Squibb: A New Opportunity for Value Investors
- Valuation Appeal: Bristol Myers Squibb's forward P/E ratio stands at approximately 9.5, significantly lower than competitors like Johnson & Johnson at 21 and Merck at 24, indicating its potential as a value stock that may attract investors seeking undervalued opportunities.
- Stable Dividend Yield: The company boasts a dividend yield of 4.2% and has increased its dividend for 17 consecutive years while paying dividends for 94 years, showcasing its financial stability and commitment to shareholders, which could bolster investor confidence.
- Revenue Growth and Challenges: While revenue from its legacy portfolio dropped from $25.7 billion in 2024 to $21.8 billion in 2025, revenue from its growth portfolio surged from $22.6 billion to $26.4 billion, indicating potential in new drug development that may alleviate future revenue pressures.
- Acquisition Strategy: Bristol's $1.5 billion acquisition of Orbital Therapeutics, despite its $47 billion debt, could enhance its drug pipeline, particularly in RNA therapeutics, with the market projected to reach $205 billion by 2035, reflecting its long-term growth potential.
See More
Market Faces Multiple Challenges and Opportunities
- Impact of Iran War: Since the onset of the Iran war, oil prices have doubled, and despite a significant drop following the two-week ceasefire news, the S&P 500 remains only 2.3% below its all-time high, indicating market resilience and adaptability to rising oil prices.
- Tech Stock Turmoil: Software stocks like ServiceNow and Salesforce have plummeted by 30% to 40% despite strong profitability due to fears of AI's impact, while hardware stocks have surged by 50% to 150%, reflecting a stark divergence in market sentiment towards the tech sector.
- Bond Market Stability: The 10-year Treasury yield peaked at 4.5% on March 27 before settling at 4.32%, with the low-rate environment providing support for the stock market, even as discussions about Federal Reserve policies remain prevalent.
- Bank Earnings Season: Goldman Sachs is set to report earnings, expected to showcase a stronger narrative than traditional banks, while Wells Fargo's performance may be influenced by market underestimations of its historical issues, potentially leading to more realistic expectations.
See More
Iran War Uncertainty Impacts Markets Ahead of Earnings Season
- Iran Talks Fail: Peace negotiations between the U.S. and Iran, led by Vice President JD Vance, ended without an agreement, increasing market concerns about the blockade of the Strait of Hormuz, which could affect 20% of global oil exports and drive prices higher.
- Earnings Season Approaches: Major companies like Goldman Sachs, Wells Fargo, and Johnson & Johnson are set to report earnings this week, with analysts focusing on Goldman’s deal-making environment and trading desk performance, expecting EPS of $16.49 and revenues of $16.97 billion.
- Wells Fargo Faces Headwinds: Wells Fargo's earnings report comes amid low market expectations due to significant exposure to non-depository financial institutions, with analysts forecasting revenues of $21.77 billion and EPS of $1.58, while looking for guidance on net interest income.
- Inflation Data Release: The Producer Price Index (PPI) will be released this week, expected to show a 1.2% month-over-month increase and a 4.6% annual rise, reflecting the impact of the Iran war on energy prices, prompting investors to watch for cost pass-through to consumers.
See More
Strong Growth Amidst Significant Challenges for Johnson & Johnson
- Consistent Revenue Growth: Despite facing challenges such as patent expirations and drug pricing negotiations, Johnson & Johnson is projected to exceed $100 billion in revenue for 2023, demonstrating resilience and a strong market position in a tough environment.
- Significant Patent Risks: Johnson & Johnson lost patent protection for Stelara in 2023, which peaked at $10.9 billion in sales, accounting for nearly 13% of total revenue, posing a potential threat to future earnings.
- Robust Financial Foundation: The company holds an AAA rating from S&P Global, indicating a strong financial position capable of weathering potential lawsuits and market fluctuations, thereby enhancing investor confidence.
- Stable Dividend Policy: With 63 consecutive years of dividend increases, Johnson & Johnson is an ideal choice for investors seeking stable income amid economic uncertainty, further solidifying its leadership in the healthcare sector.
See More
Bristol Myers Squibb: A New Value Investment Choice
- Valuation Appeal: Bristol Myers Squibb's forward P/E ratio of approximately 9.5 makes it an attractive value stock compared to competitors like Johnson & Johnson and Merck, which have ratios of 21 and 24, potentially drawing interest from value-focused investors.
- Stable Dividend Yield: With a dividend yield of 4.2% and a history of 94 consecutive years of dividend payments, including 17 years of increases, the company demonstrates strong cash flow and commitment to shareholders, bolstering investor confidence.
- Revenue Growth Potential: While revenue for 2024 and 2025 is projected at $48.3 billion and $48.2 billion respectively, with a decline expected in 2026 to between $46 billion and $47.5 billion, the growth portfolio's revenue increased from $22.6 billion to $26.4 billion, indicating strong potential in new drug development.
- Acquisition Strategy: The planned $1.5 billion acquisition of Orbital Therapeutics, despite the existing $47 billion debt, could enhance Bristol's pipeline and help mitigate revenue losses from upcoming patent cliffs, showcasing a strategic vision for long-term growth.
See More
Investment Analysis of Bristol Myers Squibb
- Stable Revenue Performance: Bristol Myers Squibb reported revenues of $48.3 billion in 2024 and $48.2 billion in 2025, with a projected decline to between $46 billion and $47.5 billion in 2026, yet its revenue stability continues to attract investor interest.
- High Dividend Appeal: The company boasts a dividend yield of 4.2%, significantly higher than its competitors, and has increased its dividend for 17 consecutive years while paying dividends for 94 years, demonstrating strong cash flow and shareholder return capabilities.
- Growth Potential and Acquisition Plans: Bristol plans to acquire Orbital Therapeutics for $1.5 billion, which, despite its $47 billion debt, could enhance its drug pipeline and help mitigate revenue losses from upcoming patent cliffs.
- Market Concerns and Value Investment: While the market is worried about declining revenue from its legacy portfolio, Bristol's growth portfolio saw an increase from $22.6 billion to $26.4 billion in 2025, indicating potential in new drug development that may offer long-term value for investors.
See More
Bristol Myers Squibb: A New Opportunity for Value Investors
- Valuation Appeal: Bristol Myers Squibb's forward P/E ratio stands at approximately 9.5, significantly lower than competitors like Johnson & Johnson at 21 and Merck at 24, indicating its potential as a value stock that may attract investors seeking undervalued opportunities.
- Stable Dividend Yield: The company boasts a dividend yield of 4.2% and has increased its dividend for 17 consecutive years while paying dividends for 94 years, showcasing its financial stability and commitment to shareholders, which could bolster investor confidence.
- Revenue Growth and Challenges: While revenue from its legacy portfolio dropped from $25.7 billion in 2024 to $21.8 billion in 2025, revenue from its growth portfolio surged from $22.6 billion to $26.4 billion, indicating potential in new drug development that may alleviate future revenue pressures.
- Acquisition Strategy: Bristol's $1.5 billion acquisition of Orbital Therapeutics, despite its $47 billion debt, could enhance its drug pipeline, particularly in RNA therapeutics, with the market projected to reach $205 billion by 2035, reflecting its long-term growth potential.
See More
Market Faces Multiple Challenges and Opportunities
- Impact of Iran War: Since the onset of the Iran war, oil prices have doubled, and despite a significant drop following the two-week ceasefire news, the S&P 500 remains only 2.3% below its all-time high, indicating market resilience and adaptability to rising oil prices.
- Tech Stock Turmoil: Software stocks like ServiceNow and Salesforce have plummeted by 30% to 40% despite strong profitability due to fears of AI's impact, while hardware stocks have surged by 50% to 150%, reflecting a stark divergence in market sentiment towards the tech sector.
- Bond Market Stability: The 10-year Treasury yield peaked at 4.5% on March 27 before settling at 4.32%, with the low-rate environment providing support for the stock market, even as discussions about Federal Reserve policies remain prevalent.
- Bank Earnings Season: Goldman Sachs is set to report earnings, expected to showcase a stronger narrative than traditional banks, while Wells Fargo's performance may be influenced by market underestimations of its historical issues, potentially leading to more realistic expectations.
See More
Iran War Uncertainty Impacts Markets Ahead of Earnings Season
- Iran Talks Fail: Peace negotiations between the U.S. and Iran, led by Vice President JD Vance, ended without an agreement, increasing market concerns about the blockade of the Strait of Hormuz, which could affect 20% of global oil exports and drive prices higher.
- Earnings Season Approaches: Major companies like Goldman Sachs, Wells Fargo, and Johnson & Johnson are set to report earnings this week, with analysts focusing on Goldman’s deal-making environment and trading desk performance, expecting EPS of $16.49 and revenues of $16.97 billion.
- Wells Fargo Faces Headwinds: Wells Fargo's earnings report comes amid low market expectations due to significant exposure to non-depository financial institutions, with analysts forecasting revenues of $21.77 billion and EPS of $1.58, while looking for guidance on net interest income.
- Inflation Data Release: The Producer Price Index (PPI) will be released this week, expected to show a 1.2% month-over-month increase and a 4.6% annual rise, reflecting the impact of the Iran war on energy prices, prompting investors to watch for cost pass-through to consumers.
See More
